Recursion Pharmaceuticals
RXRX
RXRX
146 hedge funds and large institutions have $1.21B invested in Recursion Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 63 increasing their positions, 29 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
10% more funds holding
Funds holding: 133 → 146 (+13)
3.87% more ownership
Funds ownership: 64.98% → 68.85% (+3.9%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
Holders
146
Holding in Top 10
8
Calls
$1.1M
Puts
$455K
Top Buyers
| 1 | +$25.9M | |
| 2 | +$16.2M | |
| 3 | +$15.1M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.8M |
| 5 |
DFO
Duquesne Family Office
New York
|
+$11.8M |
Top Sellers
| 1 | -$21.2M | |
| 2 | -$9.61M | |
| 3 | -$4.01M | |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$3.87M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$3.02M |